An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

Hoffmann-La Roche197 enrolled

Overview

This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.

Study Type

OBSERVATIONAL

Enrollment

197

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, over 18 years of age * Moderate to severe rheumatoid arthritis * RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form Exclusion Criteria: * Patients with rheumatic autoimmune disease other than rheumatoid arthritis * Patients who are not willing to sign the informed consent form * Patients who participate in interventional trials during the period of this observational study

Locations (13)

Unnamed facility

Athens, Greece

Unnamed facility

Athens, Greece

Unnamed facility

Athens, Greece

Unnamed facility

Crete, Greece

Outcomes

Primary Outcomes

Percentage of patients who remained under continued RoActemra/Actemra treatment

Time frame: 6 months

Secondary Outcomes

Reasons for withdrawal

Time frame: 6 months

Frequency of withdrawal

Time frame: 6 months

Frequency of dose modification

Time frame: 6 months

Reasons for dose modification

Time frame: 6 months

Safety: Incidence of adverse events

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.